Needham & Company Adds Apellis Pharmaceuticals (APLS) to Conviction List, Calls Top Pick for 2022
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $70.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
